TGEN Tecogen Inc

Targeted Genetics Corporation (Nasdaq:TGEN) announced today that it will present at the Needham & Company 5th Annual Biotechnology and Medical Technology Conference on Thursday, June 15, 2006, at 1:30 p.m. Eastern Time. The conference is being held at the New York Palace Hotel. H. Stewart Parker, President and Chief Executive Officer, will provide a corporate overview, including an update to the Company's lead product development program for inflammatory arthritis and other corporate activities. To access the live audio webcast for this conference, please log on to the Company's website at http://www.targetedgenetics.com to register and download any necessary software. The audio presentation and slideshow will be available for replay following the event. Additional information about the Needham & Company conference can be found at www.needhamco.com. About Targeted Genetics Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative targeted molecular therapies for the prevention and treatment of inflammatory arthritis, HIV/AIDS and other acquired and inherited diseases with significant unmet medical need. Targeted Genetics uses its considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Its product development efforts target inflammatory arthritis, HIV/AIDS, congestive heart failure, Huntington's disease, and hyperlipidemia. To learn more about Targeted Genetics, visit its website at www.targetedgenetics.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements regarding our business strategy, our product development and other statements about our plans, objectives, intentions and expectations. In particular, the statements regarding the Company's future plans are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, our ability to raise capital when needed, potential development of alternative technologies or more effective products by competitors, the timing, enrollment of patients, nature and results of our clinical trials our ability to obtain and maintain regulatory or institutional approvals, and our ability to obtain, maintain and protect our intellectual property, as well as other risk factors described our periodic reports we file with the Securities and Exchange Commission. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.